How Quitting Smoking Can Quickly Lower Risk Of A-Fib
Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.
Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."
"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.
The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.
"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.
The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.
Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:
1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.
2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.
3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.
4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.
5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.
6. Drinking water can help flush nicotine out of your system faster, reducing cravings.
7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.
Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.
Credit: www.wegovy.com
People in the UK can, from today, access the Wegovy weight loss pill through pharmacies with a doctor's prescription. It is the first oral glucagon-like peptide-1 (GLP-1) medicine approved in the UK for weight loss.
The Medicines and Healthcare products Regulatory Agency (MHRA) approved the tablet on June 11, marking the first oral GLP-1 treatment available in the country for obesity management.
"Having met the MHRA's rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management," Julian Beach, Executive Director of Healthcare Quality and Access at the MHRA, said in a statement.
"As with all GLP-1 receptor agonists, this is a prescription-only medication," Beach added.
Novo Nordisk called it an "important milestone for obesity care in the UK".
"For the first time, people living with obesity have access to a GLP-1 treatment in a daily pill, allowing them the choice and flexibility of oral treatment to support their long-term weight management," said Sebnem Avsar Tuna, General Manager at Novo Nordisk UK.
Also read: US Medicare Set To Cover GLP-1 Drugs For Weight Loss: All You Should Know About Eligibility, Costs
The semaglutide (Wegovy) tablet can be prescribed alongside a reduced-calorie diet and increased physical activity for adults who:
Patients must begin with the lowest dose of 1.5 mg once daily, which can be gradually increased to:
People currently taking 2.4 mg weekly semaglutide injections privately can switch directly to 25 mg semaglutide tablets once daily.
Read More: This 45-Minute Weight-Loss Procedure May Work Better Than Semaglutide Pills, Study Claims
According to the MHRA, the tablet should be:
Patients are advised to carefully follow the instructions in the Patient Information Leaflet.
Semaglutide is a GLP-1 receptor agonist that mimics the action of the naturally occurring GLP-1 hormone released after eating.
It acts on areas of the brain that regulate appetite by:
Not yet. Although the medicine has received MHRA approval, it is not currently available through the NHS.
The MHRA said NHS availability will depend on the usual evaluation process by the National Institute for Health and Care Excellence (NICE).
NICE said Novo Nordisk has not yet formally approached it, but that it is in active discussions with the company, BBC reported.
The most commonly reported side effects are gastrointestinal and include:
The MHRA said it will continue to monitor the medicine's safety and effectiveness. Anyone experiencing side effects should speak to their doctor, pharmacist, or nurse and report them through the MHRA Yellow Card scheme.
Community pharmacies say they are preparing for a surge in demand following the launch. The National Pharmacy Association (NPA) urged patients to obtain the medicine only from regulated pharmacies following a proper clinical consultation.
Credit: AI
The Democratic Republic of the Congo (DRC) is battling one of its deadliest Ebola outbreaks in recent years. While it is driving innovation in medical science with new clinical trials and diagnostic tests, it is also a stark reminder of the urgency to contain the outbreak as soon as possible.
According to the latest data, the death toll in DRC has now crossed 500 with at least 1,528 cases that are reported and confirmed.
While Ebola is not a new disease, the current outbreak stands apart because it is being caused by a rare strain of the virus, Bundibugyo.
Unlike previous outbreaks dominated by the Zaire strain of Ebola, the current epidemic, caused by the Bundibugyo virus, is a much less common species of the Ebola virus family.
The rarity of the strain has created unique scientific and emergency public health challenges, as there is currently no licensed vaccine designed to protect against Bundibugyo Ebola virus.
During outbreaks caused by the Zaire strain, vaccination became an important part of outbreak control. In the current epidemic, however, public health officials are being forced to rely heavily on rapid diagnosis, infection prevention, surveillance, and existing medical care.
Read more: Legionnaires' Disease Outbreak Grips NYC After At Least 14 Cases Reported Across 2 Neighborhoods
In a major scientific breakthrough, the World Health Organization (WHO) recently added the first molecular diagnostic test for the Bundibugyo Ebola virus to its Emergency Use Listing (EUL).
The test detects the virus's genetic material in blood samples, enabling laboratories to confirm infections more quickly and accurately.
WHO and its partners have launched the first clinical trial specifically evaluating treatments for Bundibugyo Ebola virus disease.
Researchers are testing the experimental monoclonal antibody MBP134, the antiviral drug remdesivir, and a combination of both to determine whether they can improve survival.
The Bundibugyo virus was first identified in Uganda in 2007 and has caused only a few outbreaks since then. As infections have been relatively uncommon compared to the Zaire strain, researchers have had limited opportunities to develop vaccines, treatments and diagnostic tests.
Due to this, healthcare workers have been compelled to rely primarily on rapid isolation of patients, intensive supportive care, contact tracing, and strict infection prevention measures to slow transmission.
Currently, Eastern DRC is the hotspot for the Bundibugyo Ebola outbreak, where conflict, population displacement, skepticism, and insecurity have made it difficult for health workers to reach affected locations.
Here, access to healthcare still remains uneven in many areas. Additionally, movement of people across districts and states in the country can accelerate the spread of infection significantly.
As scientists race to validate new diagnostics and evaluate experimental treatments, the Bundibugyo outbreak is becoming more than a public health emergency. It is also serving as a critical test of how quickly the global health community can develop and deploy new tools against an emerging infectious disease.
Credit: AI
The health authorities in New York City are currently investigating an outbreak of Legionnaires' disease after at least 14 people were diagnosed with the potentially life-threatening respiratory illness across two neighborhoods in Manhattan. The recent outbreak prompted an urgent public health response.
The outbreak, initially marked with just two cases earlier this week, has grown rapidly. Cases of infections were reported in Carnegie Hill and Yorkville on the Upper East Side.
The New York City Department of Health has immediately launched an investigation to identify the source of the outbreak and is inspecting cooling towers and other water systems in the affected areas, where the Legionella bacteria commonly thrive.
Authorities have urged residents and visitors who were in the neighborhoods in recent days to seek medical attention if they face symptoms like fever, cough or difficulty breathing.
The bacteria naturally occur in freshwater environments but can multiply in man-made water systems that are poorly maintained, including:
Read more: New Blood Test May Predict Alzheimer's Symptoms At Least 4 Years In Advance: Study
Symptoms of Legionnaire's disease appear 2 to 14 days after exposure, although they can sometimes take longer. The common symptoms of Legionnaires' disease include:
Some patients, particularly older adults, may also develop nausea, vomiting, diarrhea or confusion. As the illness closely resembles other forms of pneumonia, laboratory testing is usually required to confirm the diagnosis.
Read more: Donald Trump Posts AI Video of Himself Treating Critics for 'Derangement Syndrome'
Legionnaires' disease is treatable with antibiotics, and early diagnosis greatly improves recovery. However, delayed treatment can lead to severe complications such as respiratory failure, septic shock, or multi-organ failure.
The disease can be fatal, especially among older adults and people with underlying health conditions.
While the overall fatality rate is around 10% in otherwise healthy individuals, it can be considerably higher in vulnerable patients if treatment is delayed.
Although most people are unlikely to be exposed, experts recommend:
If you feel ill and experience the symptoms of Legionnaire's, watch for signs, especially respiratory distress, fever, or extreme tiredness. Health officials recommend the following:
New York City health officials are testing cooling towers and other potential environmental sources in the affected neighborhoods to identify where the bacteria may have originated. Property owners are immediately required to disinfect contaminated cooling towers if Legionella is detected.
Officials have emphasized that residents can continue using home air conditioners and public cooling centers, as these systems do not typically spread the bacteria in the same way as large industrial cooling towers.
© 2024 Bennett, Coleman & Company Limited